BDX

Business Context and Reporting Period

Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2001 (First Quarter of Fiscal Year 2002)
Business Overview: BD operates in three primary segments: Medical Systems, Clinical Laboratory Solutions, and Biosciences. The company manufactures and distributes medical devices, diagnostic systems, and laboratory products globally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 9% year-over-year, driven by a 10% growth in international sales and strong performance in Europe, Latin America, and Asia Pacific. Foreign currency translation had a negligible negative impact.
• Segment Performance:
  • Medical Systems: Revenues up 9%, driven by advanced protection devices and prefillable drug delivery devices. Growth was partially offset by lower diabetes syringe sales due to promotional redirection.
  • Clinical Lab: Revenues up 7%, led by advanced protection devices and molecular diagnostic platforms (BD ProbeTec ET).
  • Biosciences: Revenues up 14%, with international sales surging 25% due to immunocytometry systems and reagents.
• Profitability: Net income more than doubled to $99.7 million compared to $36.9 million in the prior year. This increase is significantly influenced by the adoption of new accounting standards (SFAS 141 and 142) which eliminated goodwill amortization, providing an approximate $0.025 per share benefit.
• Cost Structure: Selling and administrative expenses decreased as a percentage of revenue (26.3% vs. 27.2%). R&D spending was 5.8% of revenue, down from 6.1%.
• Debt and Liquidity: Total debt represented 34.2% of total capital, down from 40.8% a year ago. Net interest expense declined $9 million due to lower rates and debt levels.

Guidance, Outlook, and Risks

• Restructuring Charges: Management plans to record special charges of approximately $25 million to $28 million in the second quarter related to a small-scale restructuring of manufacturing facilities in the Medical segment.
• Capital Expenditures: Capital spending for the quarter was $50 million. Total capital spending for fiscal 2002 is expected to be approximately $300 million.
• Share Repurchases: The company repurchased 1.6 million shares for $53 million during the quarter. Authorization remains to repurchase an additional 8.4 million shares.
• Legal Proceedings:
  • Latex Cases: 510 claims received to date regarding latex glove reactions.
  • RTI Litigation: Antitrust lawsuit filed by Retractable Technologies, Inc. alleging conspiracy to exclude them from the market. The court granted BD's motion to dismiss the initial complaint, but the plaintiff filed an amended complaint. Trial is set for September 2002.
  • Class Action: Product liability lawsuits regarding needlesticks. Class certification was denied in Illinois, with the plaintiff seeking to appeal.
• Accounting Changes: Adoption of SFAS 142 eliminated goodwill amortization. The company is performing the required goodwill impairment assessment, which is not expected to have a significant impact.

Investor Verification Checklist

• Accounting Impact: Verify the specific impact of SFAS 141/142 adoption on reported earnings versus cash flow, noting the elimination of non-cash goodwill amortization.
• Upcoming Charges: Monitor the second quarter for the anticipated $25–$28 million restructuring charge in the Medical segment.
• Legal Exposure: Track the status of the RTI antitrust litigation and the outcome of the appeal in the Illinois needlestick class action case.
• Product Mix: Assess the sustainability of revenue growth in advanced protection devices versus the decline in diabetes syringe sales.
• Debt Covenants: Confirm continued compliance with interest coverage ratio covenants in the $900 million syndicated credit facilities.